Sanofi says Gaucher pill meets goals in late-stage tests
PARIS Feb 15 (Reuters) - Sanofi said on Friday its experimental pill for Gaucher disease met its main targets in two late-stage studies, which the French drugmaker will use to bolster its case for regulatory approval.
If approved, eliglustat tartrate could become the first-oral treatment for Gaucher disease, a rare genetic disorder affecting some 10,000 patients worldwide.
(Reporting by Elena Berton; Editing by Christian Plumb)
- IPhone emerges from 'bygone era', reviewers hail bigger handset
- Fed may hint on rate-hike plan as it prepares for policy turn
- Scots' support for independence lags on eve of referendum |
- Boeing, SpaceX win contracts to build 'space taxis' for NASA
- Islamic State campaign tests Obama's commitment to Mideast allies